FDA Prescription Drug User Fee Program Could Go OIG Scrutiny
This article was originally published in The Tan Sheet
Executive Summary
In addition to user fees, upcoming FDA reviews will focus on oversight of post-marketing requirements and information exchange in the drug supply chain.